Rituximab Therapy in Follicular Lymphoma in Combination With Chemotherapy - REFLECT 1
NCT02461290 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 99
Last updated 2015-09-30
Summary
The primary objective is to evaluate the safety profile and tolerability of rituximab in combination with different chemotherapy regimens.
Conditions
Interventions
- RADIATION
-
Chemotherapy
- DRUG
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Clinical Trials · Hoffmann-La Roche
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-04-30
- Primary Completion
- 2013-11-30
- Completion
- 2013-11-30
Countries
- Serbia
Study Locations
More Related Trials
-
An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma
NCT01902862 ·Status: TERMINATED ·Phase: PHASE2
-
MabThera (Rituximab) in Combination With CHOP (or CHOP-like) Chemotherapy in Patients With Aggressive B-Cell Lymphoma
NCT02486952 ·Status: COMPLETED
-
Treatment of Good Prognosis, BCL-6 Negative Diffuse Large Cell Lymphoma With CHOP-R in Patients < 61 Years Old.
NCT00429065 ·Status: UNKNOWN
-
Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT)
NCT02303119 ·Status: COMPLETED ·Phase: PHASE3
-
A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients
NCT01303887 ·Status: COMPLETED ·Phase: PHASE3
-
Rituximab and CVP Plus Interferon for Follicular Non Hodgkins Lymphoma (NHL)
NCT00842114 ·Status: COMPLETED ·Phase: PHASE2
-
Novel Combinations of CC-122, CC-223, CC-292, and Rituximab in Diffuse Large B-cell Lymphoma and Follicular Lymphoma
NCT02031419 ·Status: TERMINATED ·Phase: PHASE1
-
A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
NCT06425302 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Primary Rituximab and Maintenance
NCT00140582 ·Status: COMPLETED ·Phase: PHASE3
-
Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma
NCT01476787 ·Status: COMPLETED ·Phase: PHASE3
-
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma
NCT01856192 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
An Observational Study of First-Line Maintenance Rituximab (MabThera/Rituxan) in Participants With Follicular Non-Hodgkin's Lymphoma
NCT01684865 ·Status: COMPLETED
-
Safety and Efficacy of BKM120 in Relapsed and Refractory NHL
NCT01693614 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Safety and Efficacy of Betalutin and Rituximab in Patients With FL
NCT03806179 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma
NCT01650701 ·Status: COMPLETED ·Phase: PHASE3
-
Allogeneic Hematopoietic Stem Cell Transplantation After Reduced-intensity Conditioning for Relapsed Follicular Lymphoma
NCT01208896 ·Status: COMPLETED ·Phase: PHASE2
-
An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Follicular Lymphoma
NCT01609036 ·Status: TERMINATED
-
Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma
NCT01539174 ·Status: WITHDRAWN ·Phase: PHASE2
-
An Observational Study of MabThera/Rituxan (Rituximab) in Combination With CHOP Chemotherapy in First-Line in Patients With Diffuse Large B-Cell Lymphoma
NCT01724294 ·Status: TERMINATED
-
Rituximab and Involved Field Radiotherapy in Early Stage Follicular Lymphoma
NCT00509184 ·Status: COMPLETED ·Phase: PHASE2
-
Doxorubicin Hydrochloride Liposome and Rituximab With Combination Chemotherapy in Treating Patients With Newly Diagnosed Burkitt's Lymphoma or Burkitt-Like Lymphoma
NCT00392990 ·Status: COMPLETED ·Phase: PHASE2
-
Revlimid Dose 25 mg in Association With (R-CHOP) in the Treatment Follicular Lymphoma
NCT01393756 ·Status: COMPLETED ·Phase: PHASE2
-
Rituximab in Combination With Glofitamab and Polatuzumab Vedotin in Patients With Previously Untreated Aggressive B-cell Lymphoma Ineligible for R-CHOP
NCT05798156 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Rituximab in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Follicular Non-Hodgkin's Lymphoma
NCT00112931 ·Status: COMPLETED ·Phase: PHASE3
-
BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma
NCT02417129 ·Status: TERMINATED ·Phase: PHASE3